Metabolic disorders in menopause

Grzegorz Stachowiak, Tomasz Pertyński, Magdalena Pertyńska-Marczewska, Grzegorz Stachowiak, Tomasz Pertyński, Magdalena Pertyńska-Marczewska

Abstract

Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance - IGT, type 2 diabetes mellitus - T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women's life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases) in menopause, including the role of a tailored menopausal hormone therapy (HT). According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy). Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.

Keywords: PCOS; diabetes; insulin resistance; menopause; metabolic syndrome.

References

    1. Lobo RA, Davis SR, De Villiers TJ, et al. Prevention of diseases after menopause. Climacteric. 2014;17:540–556.
    1. Stachowiak G, Stetkiewicz T, Pertyński T. Cukrzyca u kobiet menopauzalnych. Prz Menopauzalny. 2011;10:173–180.
    1. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54:2366–2373.
    1. Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009;169:1352–1361.
    1. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641–646.
    1. Fan AZ, Dwyer J. Sex differences in the relation of HDL cholesterol to progression of carotid intima–media thickness: the Los Angeles Atherosclerosis Study. Atherosclerosis. 2007;195:e191–196.
    1. Woodard GA, Brooks MM, Barinas-Mitchell E, et al. Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women. Menopause. 2011;18:376–384.
    1. Yazdani S, Sharbatdaran M, Abedi Samakoosh M, et al. Glucose tolerance and lipid profile changes after surgical menopause. Caspian J Intern Med. 2014;5:114–117.
    1. Kabir F, Jahan N, Sultana N, Akter R. Lipid profile status in surgical menopause. J Bangladesh Soc Physiol. 2011;6:127–133.
    1. Tuna V, Alkis I, Safiye AS, et al. Variations in blood lipid profile, thrombotic system, arterial elasticity and psychosexual parameters in the cases of surgical and natural menopause. Aust N Z J Obstet Gynaecol. 2010;50:194–199.
    1. Xu Y, Lin J, Wang S, et al. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. Kaohsiung J Med Sci. 2014;30:350–361.
    1. Clark NG, Fox KM, Grandy S, SHIELD Study Group Symptoms of diabetes and their association with the risk and presence of diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) Diabetes Care. 2007;30:2868–2873.
    1. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in population of healthy, nonobese postmenopausal women. Diabetes Care. 2004;27:645–649.
    1. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:242–255.
    1. Peterlik M, Cross HS. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. Eur J Clin Nutr. 2009;63:1377–1386.
    1. Kalyani RR, Franco M, Dobs AS, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94:4127–4135.
    1. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361:1152–1163.
    1. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo controlled trial. Ann Intern Med. 2003;138:1–9.
    1. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47:1175–1187.
    1. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011;96:623–631.
    1. Puurunen J, Piltonen T, Jaakkola P, et al. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:1973–1978.
    1. Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96:2178–2185.
    1. Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011;96:1827–1834.
    1. Markopoulos MC, Valsamakis G, Kouskouni E, et al. Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. Eur J Endocrinol. 2012;168:83–90.
    1. Legro RS. Polycystic ovary syndrome. Long term sequelae and management. Minerva Ginecol. 2002;54:97–114.
    1. Velling Magnussen L, Mumm H, Andersen M, Glintborg D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertil Steril. 2011;96:1275–1280.
    1. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001;28:85–97.
    1. Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas. 2011;68:13–16.
    1. McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. 2011;13:289–301.
    1. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96:3794–3803.
    1. Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic syndrome and polycystic ovary syndrome… and vice versa. Arq Bras Endocrinol Metabol. 2009;5:227–237.
    1. Shah D, Bansal S. Polycystic ovaries – beyond menopause. Climacteric. 2014;17:109–115.
    1. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS) Hum Reprod. 2012;27:14–24.
    1. Pertyński T. Kobieta w wieku okołomenopauzalnym i pomenopauzalnym. Medycyna po Dyplomie. 1997;6:13–19.
    1. Toth MJ, Sites CK, Poehlman ET, Tchernof A. Effect of menopausal status on lipolysis: comparison of plasma glycerol levels in middle-aged, premenopausal and early, postmenopausal women. Metabolism. 2002;51:322–326.
    1. Bagnoli VR, Fonseca AM, Arie WM, et al. Metabolic disorder and obesity in 5027 Brazilian postmenopausal women. Gynecol Endocrinol. 2014;30:717–720.
    1. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol. 2007;2:31–56.
    1. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res. 2004;59:207–223.
    1. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006;3:35–42.
    1. Fournet N, Judd HL. Menopause overview. In: Wallach EE, Zacur HA, editors. Reproductive Medicine and Surgery. St. Louis: Mosby; 1995. pp. 961–981.
    1. Ben Ali S, Belfki-Benali H, Aounallah-Skhiri H, et al. Menopause and metabolic syndrome in tunisian women. Biomed Res Int. 2014;2014:457131.
    1. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas. 2008;60:10–18.
    1. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med. 2010;28:426–434.
    1. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65:262–266.
    1. Glueck CJ, Morrison JA, Wang P, Woo JG. Early and late menarche are associated with oligomenorrhea and predict metabolic syndrome 26 years later. Metabolism. 2013;62:1597–1606.
    1. Ebrahimpour P, Fakhrzadeh H, Heshmat R, et al. Metabolic syndrome and menopause: a population-based study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2010;4:5–9.
    1. Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas. 2009;62:362–365.
    1. Ziaei S, Mohseni H. Correlation between Hormonal Statuses and Metabolic Syndrome in Postmenopausal Women. J Family Reprod Health. 2013;7:63–66.
    1. Chedraui P, Pérez-López FR, Escobar GS, et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas. 2014;79:86–90.
    1. Chedraui P, Escobar GS, Pérez-López FR, et al. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014;77:370–374.
    1. Otunctemur A, Dursun M, Ozbek E, et al. Effect of Metabolic Syndrome on Sexual Function in Pre- and Postmenopausal Women. J Sex Marital Ther. 2014;13:1–10.
    1. Lobo RA. Metabolic syndrome, adipocytokines and estrogen therapy. Climacteric. 2005;8(Suppl 2):46.
    1. Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev. 1995;16:686–715.
    1. del Ghianda S, Tonacchera M, Vitti P. Thyroid and menopause. Climacteric. 2014;17:225–234.
    1. Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793–803.
    1. Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocr Pract. 2011;17:949–954.
    1. The Writing Group on behalf of the Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric. 2009;12:368–377.
    1. Stachowiak G, Zając A, Pertyński T. Zespół metaboliczny u kobiet w okresie menopauzy. Prz Menopauzalny. 2009;8:6–10.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren